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Elevated Plasma Fibrinogen Level Predicts Suboptimal
Response to Therapy With Both Single- and Double-Bolus
Eptifibatide During Percutaneous Coronary Intervention
Ehtisham Mahmud, MD, Jeffrey J. Cavendish, MD, Sotirios Tsimikas, MD, Lawrence Ang, BS,
Cuong Nguyen, MD, Guilherme Bromberg-Marin, MD, Guido Schnyder, MD, Shahin Keramati, MD,
Vachaspathi Palakodeti, MD, William F. Penny, MD, Anthony N. DeMaria, MD
San Diego, California
Objectives This study sought to determine the factors associated with suboptimal platelet inhibition (PI) with single- and
double-bolus eptifibatide during percutaneous coronary intervention (PCI).
Background Although PI  95% measured 10 min after glycoprotein IIb/IIIa inhibitor therapy is associated with improved
outcomes following PCI, this level of PI often is not achieved.
Methods We prospectively studied 150 patients undergoing PCI with single-bolus eptifibatide (180 g/kg) (n  100) and
double-bolus eptifibatide (180 g/kg administered 10 min apart) (n  50) followed by standard infusion (2 g/
kg/min). Measuring platelet aggregation at baseline and at 10 min and 30 to 45 min after eptifibatide bolus,
patients were classified as optimal responders (OPT) (95% PI) or suboptimal responders (sub-OPT) (95% PI)
based on 10-min PI after final bolus.
Results Suboptimal PI was achieved in 61% of patients with single-bolus eptifibatide and in 36% with double-bolus epti-
fibatide. In the single-bolus group, sub-OPT had higher fibrinogen levels (324  85 mg/dl vs. 259  49 mg/dl,
p  0.0002), platelet counts (221  70 vs. 186  47, p  0.008), and white blood cell counts (7.7  2.3 vs.
6.6  1.9, p  0.02). In the double-bolus group, sub-OPT also had higher fibrinogen levels (324  68 mg/dl vs.
278  53 mg/dl, p  0.01) and were more likely to be smokers (38.9% vs. 9.4%, p  0.01). Multivariable anal-
ysis showed that fibrinogen level was the only independent predictor of suboptimal PI, with fibrinogen cutoffs at
375 and 325 mg/dl predicting suboptimal PI (single-bolus: 100% and 90.0%, respectively; double-bolus: 100%
and 60%, respectively) with both doses.
Conclusions During PCI, both single- and double-bolus eptifibatide provide suboptimal PI in a substantial proportion of pa-
tients. A fibrinogen level 375 mg/dl is a strong predictor of suboptimal PI. (J Am Coll Cardiol 2007;49:
2163–71) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.019t
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Mptimal dosing of glycoprotein (GP) IIb/IIIa inhibitors is
imited by considerable heterogeneity in individual patient
esponses to therapy (1). Dosing regimens for these agents
ere initially determined in animal models based on a goal
f 80% platelet inhibition (PI) (2), a level shown to be
fficacious for abciximab (3). However, initial clinical trials
sing tirofiban (4) or eptifibatide (5) to reduce major adverse
ardiac events (MACE) during percutaneous coronary in-
rom the Division of Cardiology, University of California at San Diego, San Diego,
alifornia. There was no commercial support for this study. Drs. Mahmud and Penny
ave received clinical trial support for other studies from Accumetrics, the manufac-
urer of the rapid platelet function assay used in this study. Drs. Mahmud, Penny,
simikas, and DeMaria have received clinical trial support and research funding from
illenium Pharmaceuticals and Merck, manufacturers of glycoprotein IIb/IIIa
nhibitors. William O’Neill, MD, FACC, served as Guest Editor.h
Manuscript received March 7, 2006; revised manuscript received February 6, 2007,
ccepted March 6, 2007.erventions (PCI) yielded disappointing results, raising
uestions as to whether the doses used achieved adequate PI
6,7).
Data using point-of-care assessment of the adequacy of
I in the cardiac catheterization laboratory are sparse. In the
OLD study, using a bedside rapid platelet function assay,
he investigators examined the relationship between the
evel of PI achieved and the clinical efficacy of all 3 available
P IIb/IIIa inhibitors (8). It was observed that patients who
chieved 95% PI, measured 10 min after GP IIb/IIIa
nhibitor administration, had a MACE (death, myocardial
nfarction, urgent target vessel revascularization) rate of
.4% in the periprocedural period, whereas patients who
chieved 95% PI had a greater than twofold increased
ACE rate of 14.4%. Based on these findings, PI  95%
as been recommended to achieve the optimal therapeutic
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therapy during PCI (9). Al-
though 30% of patients in the
GOLD study had suboptimal PI,
few data are currently available to
indicate which, if any, clinical or
biological factors contribute to or
are associated with a suboptimal
response to GP IIb/IIIa inhibi-
tors (9). Accordingly, this study
was designed to determine the
proportion of patients achieving
inadequate PI with eptifibatide
and to detect the clinical/biological
factors associated with subopti-
mal PI.
ethods
tudy protocol. The study was approved by the University
f California Human Research Protection Program, and
nformed consent was obtained from all patients. One
undred fifty patients undergoing PCI in whom the GP
Ib/IIIa inhibitor eptifibatide was used for clinical indica-
ions were enrolled in the protocol. The PCI was carried out
y standard technique via the femoral artery approach.
atients with acute myocardial infarction (preceding 72 h),
hronic renal insufficiency (creatinine 1.5 mg/dl), chronic
iver disease, known malignancy, or GP IIb/IIIa inhibitor
se before PCI were excluded. Eptifibatide was adminis-
ered as a single bolus (180 g/kg) in the first 100 patients
PURSUIT [Platelet glycoprotein IIb/IIIa in Unstable an-
ina: Receptor Suppression Using Integrilin Therapy] pro-
ocol) (10) and as a double bolus (180 g/kg given 10 min
part) in the next 50 patients (ESPRIT [Enhanced Sup-
ression of the Platelet IIb/IIIa Receptor with Integrilin
herapy] protocol) (11), followed by an 18-h infusion of 2
g/kg/min. Thirty-three patients were on long-term clopi-
ogrel treatment, and 117 patients received 300 mg clopi-
ogrel immediately before PCI. All patients received intra-
enous unfractionated heparin (60 U/kg) and further doses
s required to achieve an activated clotting time of 200 to
50 s during the PCI.
aboratory studies. Baseline complete blood count, plate-
et count, fasting lipid panel, fibrinogen, C-reactive protein
CRP), creatine kinase (CK), CK-MB, and troponin I
evels were obtained in all patients. Postprocedural CK,
K-MB, and troponin I levels were measured every 8 h for
4 h or until hospital discharge (if first 2 measurements were
ormal). The complete blood count and platelet count were
erformed on a Cell-Dyn 3500 Analyzer (Abbot, Abbott
ark, Illinois). The lipid profile, CRP, and CK were
easured on a Synchron LX 20 Analyzer (Beckman
oulter, Fullerton, California) with standard reagents. The
K-MB and troponin I levels were measured on an
Abbreviations
and Acronyms
CK  creatine kinase
CRP  C-reactive protein
GP  glycoprotein
MACE  major adverse
cardiac events
OPT  optimal responders
PCI  percutaneous
coronary intervention
PI  platelet inhibition
ROC  receiver-operator
characteristic
sub-OPT  suboptimal
respondersDVIA Centaur system (Bayer, Tarrytown, New York) lith commercial reagents. Fibrinogen levels were mea-
ured on a Sysmex CA 6000 Analyzer (Dade Behring,
arburg, Germany) using commercial thrombin reagent kits.
latelet aggregation inhibition studies. Inhibition of
latelet aggregation was measured with the Ultegra rapid
latelet function assay (Accumetrics, San Diego, California)
mmediately before PCI and at 10 min and 30 to 45 min
fter single-bolus injection of eptifibatide. In the double-
olus group, measurements were made at baseline, 10 min,
0 min (10 min after second bolus dose), and 30 to 45 min
fter the first bolus of eptifibatide. The Ultegra rapid
latelet function assay is an automated, whole-blood,
artridge-based, point-of-care device that allows for the
apid and reproducible evaluation of platelet function (12)
nd has been shown to correlate with both traditional
urbidimetric platelet aggregometry and radiolabeled bind-
ng assays (13). A modified thrombin receptor activating
eptide optimized to mimic 20 mol adenosine diphos-
hate when applied in standard light transmission aggre-
ometry is used as the agonist to assess PI produced by
P IIb/IIIa inhibitors. Because calcium chelating anti-
oagulants interfere with the accurate assessment of
latelet aggregation measurement in the presence of GP
Ib/IIIa inhibitors, all blood samples were collected with
-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone
s the anticoagulant in the test tubes used for platelet
ggregation measurement in this study (14). Optimal re-
ponders (OPT) were defined as patients who achieved
95% PI measured at 10 min after final bolus administra-
ion of eptifibatide, and suboptimal responders (sub-OPT)
s those achieving 95% PI.
tatistics. The primary analysis was performed to identify
ny clinical or biological marker that could help identify
ub-OPT with eptifibatide therapy. Categorical variables
re shown as counts (percentages), whereas continuous
ariables are reported as means  SD. For categorical
ariables, a chi-square test was used to test for differences
etween the 2 groups. Logistic regression analysis was
erformed to evaluate the relationship between sub-OPT
nd any variables (single bolus eptifibatide: fibrinogen level,
latelet count, white blood cell count; double bolus eptifi-
atide: fibrinogen level, absence of hypertension, smoking
tatus) that were associated with 10-min PI 95% in
nadjusted univariate analysis (p  0.05).
A Spearman rank correlation coefficient was used to
stimate the correlation between PI achieved at 10 min after
nal eptifibatide bolus with each dosing regimen and all
ontinuous variables. Multiple regression analysis was per-
ormed for 10 min PI (continuous) as a dependent variable
ith markers that correlated with 10 min PI in unadjusted
nalysis (p  0.05). To establish a cutoff point for the
brinogen level predicting suboptimal PI at 10 min after a
ingle bolus, a receiver-operator characteristic (ROC) curve
as constructed. The fibrinogen level predicting suboptimal
esponse with 100% and 90% probability also was calcu-
ated. A 2-tailed p value 0.05 was considered to be
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June 5, 2007:2163–71 Fibrinogen Level Predicts Platelet Inhibitiontatistically significant. Data were collected and analyzed
ith the use of StatView software (version 4.5, SAS
nstitute, Cary, North Carolina).
esults
aseline and in-hospital patient characteristics. SINGLE-
OLUS EPTIFIBATIDE. One hundred patients (70 male)
ith a mean age of 62.9 9.8 years were enrolled (Table 1)
nd categorized as OPT (n  39) or sub-OPT (n  61). In
he single-bolus group, OPT and sub-OPT were compara-
le in terms of baseline demographics, including cardiovas-
ular risk factors, indications for PCI, and medications,
xcept that sub-OPT were less often treated with clopi-
ogrel (11.5% vs. 25.6%, p  0.07). Angiographic charac-
eristics such as lesion morphology, number of lesions and
essels treated, or devices/stents used were similar between
he 2 groups (data not shown). The OPT group had a PI of
8  2% at 10 min and 95  5% at 30 to 45 min after
ptifibatide administration, whereas the sub-OPT group
ad a PI of 89  4% and 91  6% at the same time
ntervals, respectively.
OUBLE-BOLUS EPTIFIBATIDE. Fifty patients (38male) with a
ean age of 59.0  10.6 years were enrolled (Table 1) and
ategorized as OPT (n 32) and sub-OPT (n 18). In the
ouble-bolus group, OPT and sub-OPT were comparable
n terms of baseline demographics, cardiovascular history,
nd indications for PCI, except sub-OPT were more likely
aseline Demographics for Single- andoub e-Bolus Eptifibatide-Treated P tients
Table 1 Baseline Demographics for Single- andDouble-Bolus Eptifibatide-Treated Patients
Variable
Single-Bolus
(n  100)
Double-Bolus
(n  50)
Age (yrs), mean  SD 62.9 9.8 59.0 10.6
Body mass index (kg/m2), mean  SD 30.0 6.0 29.7 5.8
Male gender (%) 70 76
Active smoking (%) 20 20
Family history of CAD (%) 33 24
Diabetes mellitus (%)* 42 24
Hypertension (%)† 68 68
Hyperlipidemia (%)‡ 83 84
History of PCI or CABG (%) 59 50
History of MI (%) 34 22
ACS on presentation (%)§ 46 22
Ad-hoc PCI (%) 40 40
Medications (%)
Aspirin 84 92
Clopidogrel 17 32
Statins 62 82
Beta-blockers 71 68
ACE inhibitors 54 50
Fasting blood glucose110 mg/dl or treated with oral hypoglycemic medication/insulin. †Blood
ressure140/90 mm Hg or treated with antihypertensive medication. ‡Low-density lipoprotein
holesterol130 mg/dl or treated with cholesterol-lowering medication. §Rest angina/10-min
nginal episode in previous 24 h/troponin I0.2 ng/dl. Stable angina or positive stress test as
linical presentation.
ACE angiotensin-converting enzyme; ACS acute coronary syndrome; CABG coronary arterys
ypass graft surgery; CAD  coronary artery disease; MI  myocardial infarction; PCI  percuta-
eous coronary intervention.o be smokers (38.9% vs. 9.4%, p  0.01) and less likely to
e hypertensive (50.0% vs. 78.1%, p  0.04). Angiographic
haracteristics such as lesion morphology, number of lesions
nd vessels treated, or devices/stents used were similar
etween the 2 groups (data not shown). The OPT group
ad a PI of 98  2% at 10 min (after second bolus) and
9  2% at 30 to 45 min after eptifibatide administration,
hereas the sub-OPT group had a PI of 90  3% and
5%  5% at the same time intervals, respectively. Impor-
antly, among the patients who had a PI  95% after the first
olus, 63% achieved PI  95% with the administration of the
econd bolus, whereas 37% remained suboptimally inhibited.
linical outcomes. SINGLE-BOLUS EPTIFIBATIDE. There
ere no in-hospital deaths, emergency coronary artery
ypass graft surgeries, urgent target lesion revasculariza-
ions, or cerebrovascular accidents in either group. One
atient in the sub-OPT group suffered an asymptomatic
eriprocedural myocardial infarction with a peak CK-MB
f 25 IU/l. Post-PCI troponin I elevation 0.6 ng/ml was
bserved in 33.3% (13 of 39) of OPT and 36.1% (22 of 61)
ub-OPT (p  0.78). One patient in the OPT group
equired premature discontinuation of the eptifibatide infu-
ion because of gum bleeding. In the sub-OPT group, 1
atient had a retroperitoneal bleed requiring early discon-
inuation of the infusion, whereas a second patient had a
etrograde dissection of the proximal LAD that involved the
eft main coronary artery and required stent placement in
he left main trunk. This second patient received the
tandard 18-h infusion.
OUBLE-BOLUS EPTIFIBATIDE. There were no in-hospital
eaths, emergency coronary artery bypass graft surgeries,
rgent target lesion revascularizations, or cerebrovascular
ccidents in either group. Three patients suffered a
eriprocedural myocardial infarction (OPT: 2 patients;
ub-OPT: 1 patient), whereas a post-PCI troponin I
levation 0.6 ng/ml was observed in 37.5% (12 of 32) of
PT and 22.2% (4 of 18) of sub-OPT (p  0.27),
espectively. Two patients in the OPT group developed
arge access site hematomas requiring early discontinua-
ion of eptifibatide, and 1 of these patients also required
blood transfusion.
redictors of platelet inhibition. SINGLE-BOLUS EPTIFI-
ATIDE. No clinical factor, including smoking, diabetes,
ypertension, hyperlipidemia, history of coronary revascu-
arization, or presenting with an acute coronary syndrome,
ere associated with suboptimal PI response (Table 2).
nalysis of other factors potentially affecting platelet aggre-
ation showed that sub-OPT had higher fibrinogen levels
324  85 mg/dl vs. 259  49 mg/dl, p  0.0002), platelet
ounts (221 70 vs. 186 47, p 0.008) and white blood
ell counts (7.7  2.3 vs. 6.6  1.9, p  0.02) compared
ith OPT (Table 3). Logistic regression analysis showed
nly the fibrinogen level (univariate p  0.0002, multivar-
ate p  0.006) (Fig. 1A) to be an independent predictor of
uboptimal PI (10-min PI 95%). Unlike white blood cell
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Fibrinogen Level Predicts Platelet Inhibition June 5, 2007:2163–71ount, platelet count was not independent from the fibrin-
gen level (r  0.35, p  0.0009). Therefore, logistic
egression analysis was repeated without including the
latelet count in the model, which did not weaken the
ssociation between fibrinogen and suboptimal PI (p 
.002).
atients Achieving Suboptimal Plateletnhibition With Single-B lus Eptifibatide
Table 2 Patients Achieving Suboptimal PlateletInhibition With Single-Bolus Eptifibatide
Variable Present Absent p Value
Male gender (%) 58.6 (41/70) 66.7 (20/30) 0.45
Active smoking (%) 75.0 (15/20) 57.5 (46/80) 0.15
Family history of CAD (%) 60.6 (20/33) 61.2 (41/67) 0.92
Diabetes mellitus (%)* 64.3 (27/42) 58.6 (34/58) 0.57
Hypertension (%)† 63.2 (43/68) 56.3 (18/32) 0.50
Hyperlipidemia (%)‡ 59.0 (49/83) 70.6 (12/17) 0.37
History of PCI or CABG (%) 55.9 (33/59) 68.3 (28/41) 0.21
History of MI (%) 55.9 (19/34) 63.6 (42/66) 0.45
ACS on presentation (%)§ 65.2 (30/46) 57.4 (31/54) 0.42
Ad-hoc PCI (%) 62.5 (25/40) 60.0 (36/60) 0.80
Medications (%)
Aspirin 61.9 (52/84) 56.3 (9/16) 0.67
Clopidogrel 41.2 (7/17) 65.1 (54/83) 0.07
Statins 59.7 (37/62) 63.2 (24/38) 0.73
Beta-blockers 57.7 (41/71) 69.0 (20/29) 0.23
ACE inhibitors 61.1 (33/54) 60.9 (28/46) 0.89
Fasting blood glucose110 mg/dl or treated with oral hypoglycemic medication/insulin. †Blood
ressure140/90 mm Hg or treated with antihypertensive medication. ‡Low-density lipoprotein
holesterol130 mg/dl or treated with cholesterol-lowering medication. §Rest angina/10-min
nginal episode in previous 24 h/troponin I0.2 ng/dl. Stable angina or positive stress test as
linical presentation.
Abbreviations as in Table 1.
Demographics and Biological Characteristics ofOptimal and Suboptimal Responders With Single
Table 3 Demographics and Biological CharaOptimal and Suboptimal Responder
Variable
Optimal R
(n 
Age (yrs), mean  SD 63.4
Body mass index (kg/m2), mean  SD 30.2
Platelet aggregation
PAU (baseline) 185
PAU (10 min) 3
PI (10 min) (%) 98
PAU (30–45 min) 9
PI (30–45 min) (%) 95
Lipid profile (mg/dl)
Cholesterol 155
HDL cholesterol 38
LDL cholesterol 92
Triglycerides 131
Complete blood count
White blood cell (1,000/ml) 6.6
Hemoglobin (mg/dl) 12.8
Platelet count (1,000/ml) 186
Activated clotting time (s) 261
Fibrinogen (mg/dl) 259
CRP (mg/dl) 0.6
Post-PCI cTnI0.6 ng/dl (%) 33CRP C-reactive protein; cTnI cardiac troponin I; HDL high density lipopr
PCI  percutaneous coronary intervention; PI  platelet inhibition.orrelation among hematological and biological vari-
bles. For hematological and biological variables, there was
significant correlation between 10-min PI (continuous
ariable) and the fibrinogen level (r  0.39, p  0.0002),
nd white blood cell count (r  0.19, p  0.05). No
orrelation with 10-min PI was found for platelet count,
RP level, hemoglobin, or lipid levels. After multiple
egression analysis with 10-min PI (continuous) as a depen-
ent variable, white blood cell count lost any significance,
hereas fibrinogen remained associated (r  0.37, p 
.0006).
OUBLE-BOLUS EPTIFIBATIDE. Clinical factors associated
ith suboptimal PI response were smoking (70% sub-
PT, p  0.01) and absence of hypertension (56.3%
ub-OPT, p  0.04) (Table 4). Analysis of factors
otentially affecting platelet aggregation showed that
hose in the sub-OPT group were more likely to have
igher fibrinogen levels (324  68 mg/dl vs. 278  53
g/dl, p  0.01) and to be smokers (38.9% vs. 9.4%, p 
.01) and less likely to be hypertensive (50.0% vs. 78.1%,
 0.04) compared with OPT (Table 5). After logistic
egression analysis, only the fibrinogen level (univariate
 0.01, multivariate p  0.04) (Fig. 1B) retained
tatistical significance to suboptimal PI (10-min PI
95%), whereas smoking status and not being hyperten-
ive lost any significance.
orrelation among hematological and biological vari-
bles. For hematological and biological variables, there
as a significant correlation between 10-min PI (contin-
s Eptifibatide
stics of
h Single-Bolus Eptifibatide
ers Suboptimal Responders
(n  61) p Value
62.6 10.7 0.71
29.8 5.8 0.77
186 36 0.88
20 6 Definition
89 4 Definition
16 10 Definition
91 6 Definition
167 47 0.19
38 15 0.87
96 31 0.48
169 155 0.18
7.7 2.3 0.02
12.6 1.3 0.49
221 70 0.008
256 64 0.32
324 85 0.0002
1.1 1.6 0.09
36.1 0.78-Bolu
cteri
s Wit
espond
39)
8.3
6.2
36
3
2
8
5
38
15
31
87
1.9
1.5
47
55
49
0.2
.3otein; LDL low density lipoprotein; PAU platelet aggregation unit;
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June 5, 2007:2163–71 Fibrinogen Level Predicts Platelet Inhibitionous variable) and fibrinogen level (r  0.45, p 
.005), CRP level (r  0.40, p  0.01), total choles-
erol (r  0.30, p  0.05), and LDL cholesterol (r 
0.28, p  0.05). After multiple regression analysis with
0-min PI (continuous) as a dependent variable, CRP,
otal cholesterol, and LDL cholesterol lost any signifi-
ance and fibrinogen remained associated (r  0.47, p
0.002).
OC curve. Fibrinogen level was available for 136 pa-
ients in whom PI at 10 min after the first bolus of
ptifibatide was measured. These data were used to
onstruct a ROC curve relating fibrinogen level to
uboptimal PI, and it showed an area under the curve of
.71  0.04 (Fig. 2). A nonlinear relationship existed
etween the fibrinogen level and PI achieved, with
brinogen cutoff levels of 375 mg/dl and 325 mg/dl
ielding 100% and 90% probability, respectively, of
chieving suboptimal PI with a single bolus of eptifi-
atide (Fig. 3). These same fibrinogen cutoff levels were
redictive of suboptimal PI with the double-bolus dose in
00% and 60% of patients, respectively. In the double-
olus group, 76% of the patients with a fibrinogen level
325 mg/dl achieved optimal PI, whereas only 40% of
atients with a fibrinogen level 325 mg/dl achieved
Figure 1 Fibrinogen Level by Response to
Single- and Double-Bolus Eptifibatide
(A) Fibrinogen level of optimal (OPT) and suboptimal (sub-OPT) responders
with single-bolus eptifibatide. p  0.002. (B) Fibrinogen level of OPT and
sub-OPT responders with double-bolus eptifibatide. p  0.01.ptimal PI.
piscussion
his study shows that inadequate platelet inhibition is
requently present in response to GP IIb/IIIa inhibitor
herapy with eptifibatide during PCI and that elevated
brinogen levels independently predict the adequacy of
latelet inhibition. Using the criterion of PI 95% at 10
in for optimal efficacy, single-bolus eptifibatide provides
nadequate PI in 61% of patients whereas double-bolus
rovides inadequate PI in 36% of patients. Furthermore, a
lasma fibrinogen level 375 mg/dl predicts suboptimal PI
ith 100% probability with both single- and double-bolus
osing regimens of eptifibatide. Elevated fibrinogen levels
ay mediate enhanced platelet aggregation by cross-linking
f GP IIb/IIIa receptors on platelets, thereby limiting the
fficacy of GP IIb/IIIa inhibitors, despite recommended
oses. This association between elevated fibrinogen levels
nd inadequate platelet inhibition provides insights into
otential mechanisms by which higher MACE rates are
ediated during PCI and suggests novel avenues for further
esearch in this area.
Fibrinogen plays a key role in thrombus formation (15) by
inding to the platelet receptor GP IIb/IIIa, and is respon-
ible for cross-linking platelets resulting in the formation of
latelet-rich thrombi. Although fibrinogen is known to
ffect platelet aggregation (16), the role of the fibrinogen
evel in the efficacy of GP IIb/IIIa inhibitors has not been
efined previously. Our data show that the fibrinogen level
s inversely related to the level of PI achieved with eptifi-
atide during PCI. After adjusting for multiple variables
nown to affect platelet aggregation, an elevated fibrinogen
evel was the only factor predictive of a suboptimal response
atients Achieving Suboptimal Plateletnhibition With Double-Bolus Eptifibatide
Table 4 Patients Achieving Suboptimal PlateletInhibition With Double-Bolus Eptifibatide
Variable Present Absent p Value
Male gender (%) 42.1 (16/38) 16.7 (2/12) 0.11
Active smoking (%) 70.0 (7/10) 27.5 (11/40) 0.01
Family history of CAD (%) 50.0 (6/12) 31.6 (12/38) 0.25
Diabetes mellitus (%)* 25.0 (3/12) 39.5 (15/38) 0.36
Hypertension (%)† 26.5 (9/34) 56.3 (9/16) 0.04
Hyperlipidemia (%)‡ 35.7 (15/42) 37.5 (3/8) 0.92
History of PCI or CABG (%) 36.0 (9/25) 36.0 (9/25) 1.0
History of MI (%) 36.4 (4/11) 35.9 (14/39) 0.98
ACS on presentation (%)§ 36.4 (4/11) 35.9 (14/39) 0.98
Ad-hoc PCI (%) 40.0 (8/20) 33.3 (10/30) 0.63
Medications (%)
Aspirin 34.8 (16/46) 50.0 (2/4) 0.54
Clopidogrel 25.0 (4/16) 41.1 (14/34) 0.27
Statins 31.7 (13/41) 55.5 (5/9) 0.18
Beta-blockers 32.4 (11/34) 43.8 (7/16) 0.43
ACE inhibitors 36.0 (9/25) 36.0 (9/25) 1.0
Fasting blood glucose110 mg/dl or treated with oral hypoglycemic medication/insulin. †Blood
ressure140/90 mm Hg or treated with antihypertensive medication. ‡Low-density lipoprotein
holesterol130 mg/dl or treated with cholesterol-lowering medication. §Rest angina/10-min
nginal episode in previous 24 h. Stable accelerating angina or positive stress test as clinical
resentation.
Abbreviations as in Table 1.
t
c
o
c
t
E
w
a
r
M
e
g
t
S
o
(
i
i
t
r
I
p
b
t
w
l
s
b
P
a
t
n
c
h
p
f
g
p
g
e
c
e
H
l
e
S
C
c
A
p
w
a
b
fi
i
2168 Mahmud et al. JACC Vol. 49, No. 22, 2007
Fibrinogen Level Predicts Platelet Inhibition June 5, 2007:2163–71o a single- or double-bolus dose of eptifibatide. This is
onsistent with in vitro experimental data (17) and with the
bservation by Li et al. (18) that fibrinogen supplementation
an overcome the antagonism of the GP IIb/IIIa receptor by
he small molecules eptifibatide and tirofiban.
The double-bolus regimen of eptifibatide was used in the
SPRIT (11) study to minimize the number of patients
ho had a suboptimal PI response. Although platelet
ggregation studies were not carried out in this study, the
esults of the trial were remarkable with a reduction in
ACE from 10.5% to 6.6% (p  0.0034), but at the
xpense of increased bleeding in the eptifibatide-treated
roup (4.4% vs. 2.5%, p  0.029) (19). On the other hand,
he results of TARGET (Do Tirofiban and Reopro Give
imilar Efficacy Trial) (20) did not support the hypothesis
f tirofiban noninferiority to abciximab in PCI patients
MACE being 7.7% with tirofiban and 6.0% with abcix-
mab, p  0.038), and further studies suggest that early
nadequate PI with tirofiban may have been responsible for
he higher MACE rate seen in the tirofiban group (7). The
esults of these and other studies (21) suggest that GP
Ib/IIIa inhibitors reduce MACE associated with PCI
rovided optimal PI is achieved. However, excessive PI may
e associated with increased bleeding complications. Fur-
hermore, the proportion of patients achieving optimal PI
ith short-acting GP IIb/IIIa inhibitors is unclear, and
imited data exist identifying factors associated with a
uboptimal PI response with GP IIb/IIIa inhibitors.
In this study, we examined the role of the clinical and
Demographics and Biological Characteristics ofOptimal and Suboptimal Responders With Doubl
Table 5 Demographics and Biological CharaOptimal and Suboptimal Responder
Optimal R
(n 
Age (yrs), mean  SD 60.3
Body mass index (kg/m2), mean  SD 29.5
Platelet aggregation
PAU (baseline) 215
PAU (10 min) 4
PI (10 min) (%) 98
PAU (30–45 min) 2
PI (30–45 min) (%) 99
Lipid profile (mg/dl)
Cholesterol 145
HDL cholesterol 38
LDL cholesterol 86
Triglycerides 114
Complete blood count
White blood cell (1,000/ml) 7.3
Hemoglobin (mg/dl) 14.1
Platelet count (1,000/ml) 249
Activated clotting time (s) 243
Fibrinogen (mg/dl) 278
CRP (mg/dl) 0.6
Post-PCI cTnI0.6 ng/dl (%) 37
Abbreviations as in Table 3.iological factors known to affect platelet aggregation on the bI achieved with eptifibatide. Increased tendency to platelet
ggregation is associated with smoking (22), hypercholes-
erolemia (23,24), diabetes mellitus (25), a history of coro-
ary atherosclerosis (26), and presenting with an acute
oronary syndrome (27,28). Feng et al (16) showed that
igher fibrinogen levels were also associated with increased
latelet aggregation. Although this association was specific
or the PlA1A1 genotype and not for the PlA2-positive
enotype, the PlA2-positive genotype still had a higher
latelet aggregation compared with the PlA1-homozygous
enotype.
This study establishes that a significant relation does not
xist between total cholesterol, LDL cholesterol, HDL
holesterol or triglyceride level and the PI achieved with
ptifibatide. Though in vivo work has suggested that low
DL cholesterol might be associated with increased plate-
et aggregation (29), we were unable to demonstrate this
ffect to be of clinical significance in our patient population.
imilarly, leukocytosis, thrombocytosis and an elevated
RP level (markers of inflammation) did not have a
linically relevant effect on the PI achieved with eptifibatide.
history of coronary artery disease, as evidenced by
revious revascularization (history of PCI), or presenting
ith an acute coronary syndrome and active smoking
ppeared predictive of suboptimal response to eptifibatide
ut this relation did not hold true independently of the
brinogen level.
The presence of diabetes mellitus also is associated with
ncreased platelet activation and aggregation (25), and has
us Eptifibatide
stics of
h Double-Bolus Eptifibatide
ers Suboptimal Responders
(n  18) p Value
56.7 9.8 0.25
30.1 6.1 0.53
205 55 0.55
19 5 Definition
90 3 Definition
9 9 Definition
95 5 Definition
163 43 0.16
34 9 0.24
101 37 0.16
131 96 0.52
7.6 2.1 0.61
14.1 1.1 0.87
230 54 0.21
251 55 0.39
324 68 0.01
1.0 1.4 0.06
22.2 0.27e-Bol
cteri
s Wit
espond
32)
11.0
5.7
56
6
2
3
2
43
12
35
86
2.0
1.4
48
52
53
0.1
.5een thought to be one reason for the success of GP IIb/IIIa
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June 5, 2007:2163–71 Fibrinogen Level Predicts Platelet Inhibitionnhibitors in diabetic patients (30,31). In this study, the
umber of diabetic patients was too small to adequately
ssess the effect of eptifibatide in diabetic patients. Finally,
2% of the study population was receiving chronic clopi-
ogrel therapy, and a greater percentage of these patients
ere OPT. Thienopyridines lower plasma fibrinogen by
0% (32), and this may be an additional mechanism by
Figure 2 ROC Curve Relating Fibrinogen Level and
Suboptimal Platelet Inhibition to Eptifibatide
Receiver-operator characteristic (ROC) curve relating fibrinogen level and subop-
timal platelet inhibition response to eptifibatide first bolus dose. AUC  area
under the curve.
Figure 3 Fibrinogen Levels Predictive of Suboptimal Platelet In
Fibrinogen level predictive of suboptimal response (platelet inhibition 95% as ind
red line) to first bolus eptifibatide with 90% and 100% probability is 325 mg/dl anhich pretreatment with clopidogrel augments the anti-
latelet effects of GP IIb/IIIa inhibitors. Therefore, it is
ossible that chronic treatment or pretreatment (600 mg 2
o 3 h before PCI) with clopidogrel would enable a greater
ercentage of patients to achieve optimal PI with eptifibatide.
tudy limitations. A difference in clinical events between
he OPT and sub-OPT groups with either dosing regimen
ould not be addressed because of the small sample size and
ow adverse event rates. The sample size particularly limits
he ability to include statistical controls for many variables
imultaneously. It is possible that a larger patient cohort
ould have shown that diabetes, smoking, and lack of
retreatment with clopidogrel were independent predictors
f a suboptimal response to eptifibatide therapy. Although
ur finding that serum fibrinogen level is inversely related to
latelet inhibition achieved with eptifibatide needs to be
eplicated, a post-hoc power analysis for the ROC curve
ndicates a power of 0.99 for the detection of the observed
ffect. Genetic polymorphisms in the GP IIb/IIIa receptor
ere not addressed in this study, and suboptimal responders
ith an elevated fibrinogen level may have had a polymor-
hism of the GP IIIa PlA receptor. However, this is likely to
lay a minor role because it previously has been noted that
n increased fibrinogen level also is known to affect platelet
ggregation independently of the PlA2 allele (16).
linical implications. This observation forms the basis for
strategy of tailored dosing of GP IIb/IIIa inhibitors in
atients depending on the fibrinogen level. Routine double-
olus eptifibatide for optimal PI effect may be unnecessary
nd may expose some patients to a higher bleeding risk.
ased on this study, if a second bolus of eptifibatide were
iven at 10 min to all PCI patients, as is currently recom-
ended, 39% of the patients, who achieved optimal PI with
single bolus, could be exposed to an unnecessary risk of
leeding. It also seems that a second bolus of eptifibatide is
on With Eptifibatide
by
mg/dl, respectively.hibiti
icated
d 375
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Fibrinogen Level Predicts Platelet Inhibition June 5, 2007:2163–71ost effective in increasing the likelihood of achieving
ptimal PI in patients with a fibrinogen level 325 mg/dl,
hereas in patients with higher fibrinogen levels an addi-
ional second bolus may not be sufficient. Conversely, a
ingle bolus dose of eptifibatide may be sufficient in stable
atients with a low fibrinogen level. Because a low fibrino-
en level also is not consistently predictive of optimal PI,
ne could use a point-of-care rapid platelet function assay in
ptimally dosing GP IIb/IIIa inhibitor therapy for both
CS and PCI patients. Most patients with fibrinogen levels
325 mg/dl could be treated with a single bolus dose of
ptifibatide, and only patients with suboptimal PI would
eceive an additional bolus dose.
onclusions
e show that single-bolus eptifibatide provides inadequate
latelet inhibition in 61% of patients undergoing PCI,
hereas double-bolus eptifibatide provides inadequate
latelet inhibition in 36% of patients. An elevated fibrino-
en level is the major determinant of suboptimal platelet
nhibition with eptifibatide, and among patients with a
brinogen level375 mg/dl, no patients achieve optimal PI
ith either the single- or the double-bolus dosing regimen.
n patients with a fibrinogen level 325 mg/dl, only 10%
chieve optimal platelet inhibition with single-bolus eptifi-
atide, whereas 40% achieve it with double-bolus eptifibatide.
latelet inhibition achieved with eptifibatide during PCI is
ot related to clinical presentation, CRP, lipid level, or
resence of diabetes. Discontinuing smoking and pretreat-
ent with clopidogrel may allow a greater proportion of
atients to achieve optimal PI with both single- and
ouble-bolus eptifibatide dosing regimens. These data
rovide therapeutic targets for optimizing the efficacy of
P IIb/IIIa inhibitor use in the cardiac catheterization
aboratory.
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